TPST

Tempest Therapeutics, Inc.

3.62 USD
-0.03 (-0.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tempest Therapeutics, Inc. stock is down -8.12% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jan 15:34 16 Feb, 2024 2.50 CALL 498 145
11 Jan 20:38 16 Feb, 2024 2.50 CALL 364 145
12 Jan 19:06 19 Jan, 2024 2.50 CALL 160 2651
12 Jan 19:16 19 Jan, 2024 2.50 CALL 200 2651
12 Jan 19:21 19 Jan, 2024 2.50 CALL 200 2651
12 Jan 20:38 19 Jan, 2024 2.50 CALL 155 2651
16 Jan 14:45 19 Apr, 2024 2.50 CALL 199 101
16 Jan 16:43 19 Jan, 2024 2.50 CALL 140 924
16 Jan 17:34 19 Apr, 2024 2.50 CALL 200 101
06 Feb 20:13 19 Jul, 2024 7.50 PUT 133 1

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.